Kopion Asset Management LLC boosted its position in shares of Trupanion, Inc. (NASDAQ:TRUP - Free Report) by 18.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 281,072 shares of the financial services provider's stock after purchasing an additional 44,285 shares during the period. Trupanion makes up 8.2% of Kopion Asset Management LLC's holdings, making the stock its biggest holding. Kopion Asset Management LLC owned 0.66% of Trupanion worth $10,476,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Amundi lifted its holdings in shares of Trupanion by 193.2% in the 4th quarter. Amundi now owns 16,828 shares of the financial services provider's stock worth $784,000 after acquiring an additional 11,088 shares during the last quarter. Barclays PLC raised its position in Trupanion by 259.2% in the third quarter. Barclays PLC now owns 65,498 shares of the financial services provider's stock valued at $2,750,000 after purchasing an additional 47,262 shares during the period. Vanguard Group Inc. raised its position in Trupanion by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 3,596,725 shares of the financial services provider's stock valued at $173,362,000 after purchasing an additional 45,653 shares during the period. Dimensional Fund Advisors LP lifted its stake in Trupanion by 112.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 273,910 shares of the financial services provider's stock worth $13,204,000 after purchasing an additional 144,828 shares in the last quarter. Finally, Wealthfront Advisers LLC purchased a new position in shares of Trupanion during the fourth quarter worth $845,000.
Insiders Place Their Bets
In related news, CFO Fawwad Qureshi sold 2,534 shares of the business's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $48.31, for a total transaction of $122,417.54. Following the completion of the transaction, the chief financial officer now owns 3,545 shares in the company, valued at approximately $171,258.95. The trade was a 41.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Emily Dreyer sold 14,025 shares of Trupanion stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $32.41, for a total value of $454,550.25. Following the sale, the senior vice president now directly owns 27,645 shares of the company's stock, valued at $895,974.45. This trade represents a 33.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,487 shares of company stock worth $1,538,966 in the last 90 days. Corporate insiders own 5.42% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on TRUP shares. Piper Sandler cut their price objective on Trupanion from $57.00 to $52.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Lake Street Capital cut their price target on shares of Trupanion from $65.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Stifel Nicolaus reduced their price target on shares of Trupanion from $44.00 to $41.00 and set a "hold" rating on the stock in a research report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $51.80.
Get Our Latest Report on Trupanion
Trupanion Stock Down 0.4%
TRUP traded down $0.21 on Wednesday, hitting $49.17. 198,282 shares of the company were exchanged, compared to its average volume of 608,667. The firm has a 50-day moving average price of $40.31 and a two-hundred day moving average price of $43.80. The company has a current ratio of 1.71, a quick ratio of 1.66 and a debt-to-equity ratio of 0.39. Trupanion, Inc. has a twelve month low of $25.90 and a twelve month high of $57.90. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -213.78, a price-to-earnings-growth ratio of 6.02 and a beta of 1.72.
Trupanion (NASDAQ:TRUP - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The financial services provider reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. Trupanion had a negative return on equity of 3.08% and a negative net margin of 0.75%. The business had revenue of $341.98 million during the quarter, compared to the consensus estimate of $337.81 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The business's revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities analysts predict that Trupanion, Inc. will post 0.13 earnings per share for the current year.
Trupanion Profile
(
Free Report)
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
See Also

Before you consider Trupanion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trupanion wasn't on the list.
While Trupanion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.